Literature DB >> 32514648

Efficiency comparison of experimental fosfatriclaben with three commercial fasciolicides in experimentally infected sheep.

Rosa Arias-García1, Yolanda Vera-Montenegro1, Miguel Flores-Ramos1, Rafael Castillo2, Alicia Hernández-Campos2, Froylán Ibarra-Velarde3.   

Abstract

In this work, we compare and evaluate the efficiency of fosfatriclaben with three commercial fasciolicides in experimentally infected sheep. Fosfatriclaben is a novel prodrug derived from triclabendazole; it is highly water-soluble with excellent aqueous stability at pH 7, properties that make it ideal for developing intramuscular pharmaceutical compositions in the form of solutions. In order to compare, 30 mixed breed sheep, previously diagnosed negative to fluke eggs, were infected with 200 metacercariae of Fasciola hepatica, twice. Five groups of six animals/each were formed for treatments. Group 1 (G1) was treated with closantel 5% injectable at 5 mg/kg subcutaneously, G2 with clorsulon at 2 mg/kg subcutaneously, G3 with triclabendazole at 12 mg/kg per os, G4 with fosfatriclaben at 6 mg/kg intramuscularly (dose equivalent to triclabendazole content), and G5 remained as the non-treated control. On day 110, fecal samples were examined to determine the percentage of egg reduction after treatment, and sheep were humanely euthanized. The livers were collected, the flukes were extracted, measured, and counted. Efficiency in egg reduction was of 86.8, 90.5, 98.4, and 97.3% for closantel, clorsulon, triclabendazole, and fosfatriclaben, respectively, and efficiency against flukes was of 96.2, 91.9, 99.4, and 95.7%, respectively. No statistical differences were found between treatments. It is concluded that fosfatriclaben at 6 mg/kg intramuscularly presented a high fasciolicide efficiency, similar to the best commercial fasciolicides, having advantage over its predecessor since it uses half of the dose required by triclabendazole to remove flukes in sheep under study.

Entities:  

Keywords:  Benzimidazole; Fasciola hepatica; Fosfatriclaben; Triclabendazole; Veterinary prodrug

Mesh:

Substances:

Year:  2020        PMID: 32514648     DOI: 10.1007/s00436-020-06705-4

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  18 in total

Review 1.  Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.

Authors:  Marc Lindenberg; Sabine Kopp; Jennifer B Dressman
Journal:  Eur J Pharm Biopharm       Date:  2004-09       Impact factor: 5.571

2.  Impact of compound alpha treatment in vivo on egg production by the liver fluke, Fasciola hepatica.

Authors:  M McConville; R E B Hanna; G P Brennan; H W J Edgar; S McConnell; M McCoy; R Castillo; A Hernández-Campos; I Fairweather
Journal:  Vet Parasitol       Date:  2011-12-28       Impact factor: 2.738

Review 3.  Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.

Authors:  James H Fischer; Tejal V Patel; Patricia A Fischer
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 4.  Fasciolicides: efficacy, actions, resistance and its management.

Authors:  I Fairweather; J C Boray
Journal:  Vet J       Date:  1999-09       Impact factor: 2.688

5.  High prevalence of fasciolosis and evaluation of drug efficacy against Fasciola hepatica in dairy cattle in the Maffra and Bairnsdale districts of Gippsland, Victoria, Australia.

Authors:  T P Elliott; J M Kelley; G Rawlin; T W Spithill
Journal:  Vet Parasitol       Date:  2015-02-23       Impact factor: 2.738

6.  Fasciola gigantica transmission in the zoonotic fascioliasis endemic lowlands of Guilan, Iran: experimental assessment.

Authors:  Keyhan Ashrafi; Santiago Mas-Coma
Journal:  Vet Parasitol       Date:  2014-07-21       Impact factor: 2.738

7.  An evaluation of the efficacy of compound alpha and triclabendazole against two isolates of Fasciola hepatica.

Authors:  M McConville; G P Brennan; A Flanagan; H W J Edgar; R E B Hanna; M McCoy; A W Gordon; R Castillo; A Hernández-Campos; I Fairweather
Journal:  Vet Parasitol       Date:  2009-02-12       Impact factor: 2.738

8.  Treatment of immature and mature Fasciola hepatica infections in sheep with triclabendazole.

Authors:  J C Boray; P D Crowfoot; M B Strong; J R Allison; M Schellenbaum; M Von Orelli; G Sarasin
Journal:  Vet Rec       Date:  1983-10-01       Impact factor: 2.695

9.  Determination of the effective dose of an experimental fasciolicide in naturally and experimentally infected cattle.

Authors:  Froylán Ibarra; Yolanda Vera; Héctor Quiroz; Jorge Cantó; Rafael Castillo; Alicia Hernández; Pedro Ochoa
Journal:  Vet Parasitol       Date:  2004-02-26       Impact factor: 2.738

Review 10.  Current Threat of Triclabendazole Resistance in Fasciola hepatica.

Authors:  Jane M Kelley; Timothy P Elliott; Travis Beddoe; Glenn Anderson; Philip Skuce; Terry W Spithill
Journal:  Trends Parasitol       Date:  2016-04-02
View more
  1 in total

1.  Field study on the determination of the effective dose of injectable fosfatriclaben prodrug in sheep naturally infected with Fasciola hepatica.

Authors:  Froylán Ibarra-Velarde; Tania Rojas-Campos; Yolanda Vera-Montenegro; Miguel Flores-Ramos; Rafael Castillo; Gerardo Leyva-Gómez
Journal:  Parasitol Res       Date:  2021-11-05       Impact factor: 2.289

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.